romidepsin,pembrolizumab
merck
['romidepsin', 't-cell lymphoma', 'lymphoma', 'pembro']
in a phase i/ii study led by our dr. swaminathan iyer, researchers found combining pembrolizumab and romidepsin shows high response rates for t-cell lymphomas. dr. owhofasa agbedia presents results at #ash22: #endcancer 
MD Anderson is a global leader in cancer care, research, education and training, and prevention. Appointments available: 1-877-632-6789